High Risk Factors and Sentinel Lymph Node Biopsy in Cutaneous Squamous Cell Carcinoma: Analysis of Prevalence and Recurrence

Oltulu, Pembe

doi:10.30733/std.2018.01093

Cited by 2 publications

(2 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lymph node in the body region to which a malignant tumor first drains is named as sentinel lymph node (SLN). The importance of SLN sampling in identification of the occult lymph node metastases has been established, and accepted as a prognostic factor (35). A limitation of this study is that we could not evaluate SLN status due to the few numbers of patient populations with SLN biopsy indication.…”

Section: Discussionmentioning

confidence: 95%

Clinicopathological characteristics and mutation profile of BRAF and NRAS mutation in cutaneous melanomas in the Western Turkish population

Evrenos¹,

Temız²,

Çam³

et al. 2018

Turk J Med Sci

View full text Add to dashboard Cite

Materials and Methods 2.1. Tumor Samples Formalin-fixed paraffin-embedded (FFPE) blocks of patients diagnosed as MM between 2006 and 2013 were Background/aim: Malignant melanoma is the most common cause of death due to skin cancers. The most common mutations in RAF-RAS pathway from tumor oncogenes are BRAF and NRAS. In this study, we analyzed the frequency of BRAF and NRAS gene mutations and investigated their association with clinicopathological features of melanomas in the Turkish population. Materials and methods: 65 primary cutaneous melanoma were included in the study. The mutations were evaluated with real-time PCRbased PCR-array through allele-specific amplification, and the results were correlated with various clinicopathological characteristics. Results: 52.3% of the patients were female and 47.7% were male. The mean age of the patients with a mutation was lower than those without mutation. 16 patients had BRAF mutation. 12 patients had NRAS mutation. NRAS mutation was statistically more common in men (P = 0.036). The number of mitoses increased with the increase of the tumor thickness (P = 0.003). There was more mitosis in the presence of ulceration (P = 0.05). A total of 41.7% of NRAS mutations had adjuvant chemotherapy. Conclusion: We found lower mutation rate when compared to regional studies. NRAS mutation was common in men. This is the first study from our region evaluating the prognostic value of clinical stage and necessity of adjuvant treatment with the presence of BRAF and NRAS mutations.

show abstract

Section: Discussionmentioning

confidence: 95%

Clinicopathological characteristics and mutation profile of BRAF and NRAS mutation in cutaneous melanomas in the Western Turkish population

Evrenos¹,

Temız²,

Çam³

et al. 2018

Turk J Med Sci

View full text Add to dashboard Cite

show abstract

“…SLN positivity itself has been accepted as a prognostic factor for tumor recurrence and poor prognosis. 34 NRAS ‐mutant tumors are likely to act aggressively, especially in the early stages in the high‐risk melanoma population. In our study, 45 (88%) patients had lymph node metastasis.…”

Section: Discussionmentioning

confidence: 99%

The frequency and clinicopathological significance of NRAS mutations in primary cutaneous nodular melanoma in Indonesia

et al. 2021

View full text Add to dashboard Cite

Background: Melanoma is a lethal skin malignancy with a high risk of metastasis, which prompts a need for research on treatment targets and prognostic factors. Recent studies show that the presence of neuroblastoma RAS viral oncogene homolog (NRAS) mutation can influence cell growth in melanomas. The NRAS mutation, which stimulates the mitogen-activated protein kinase (MAPK) signaling pathway, is associated with a lower survival rate. However, evidence from Indonesia population is still very rare. Further understanding of the role of NRAS mutations in Indonesian melanoma cases will be crucial in developing new management strategies for melanoma patients with NRAS mutations.Aims: To explore the frequency of NRAS mutations and their clinicopathological associations in patients with primary nodular cutaneous melanoma in Central Java and Yogyakarta, Indonesia.Methods and results: Fifty-one paraffin-embedded tissue samples were collected from primary nodular skin melanoma cases between 2011 and 2019 from the two largest referral hospitals in Yogyakarta and Central Java, Indonesia. The NRAS mutation status was evaluated using qualitative real-time polymerase chain reaction (qRT-PCR). The association of NRAS mutation was analyzed with the following: age, gender, location, lymph node metastasis, ulceration, mitotic index, tumor-infiltrating lymphocytes (TILs), necrosis, tumor thickness, lymphovascular invasion (LVI), and tumor size. NRAS mutations were detected in 10 (19.6%) samples and predominantly observed (60%) in exon 2 (G12). These mutations were significantly correlated with lymph node metastases (p = .000); however, they were not associated with other variables analyzed in this study. Conclusions:The prevalence of NRAS mutations in primary nodular cutaneous melanoma cases from Indonesia is consistent with previous studies and is significantly associated with increased lymph node metastases. However, the predominant mutation detected in exon 2 (G12) is different from previous studies conducted in other countries. This suggests that melanoma cases in Javanese people have different characteristics from other ethnicities.

show abstract

High Risk Factors and Sentinel Lymph Node Biopsy in Cutaneous Squamous Cell Carcinoma: Analysis of Prevalence and Recurrence

Cited by 2 publications

References 16 publications

Clinicopathological characteristics and mutation profile of BRAF and NRAS mutation in cutaneous melanomas in the Western Turkish population

Clinicopathological characteristics and mutation profile of BRAF and NRAS mutation in cutaneous melanomas in the Western Turkish population

The frequency and clinicopathological significance of NRAS mutations in primary cutaneous nodular melanoma in Indonesia

Contact Info

Product

Resources

About